Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 4.18
ALNY's Cash to Debt is ranked lower than
64% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 59.90 vs. ALNY: 4.18 )
Ranked among companies with meaningful Cash to Debt only.
ALNY' s Cash to Debt Range Over the Past 10 Years
Min: 4.18  Med: No Debt Max: No Debt
Current: 4.18
Equity to Asset 0.73
ALNY's Equity to Asset is ranked higher than
57% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. ALNY: 0.73 )
Ranked among companies with meaningful Equity to Asset only.
ALNY' s Equity to Asset Range Over the Past 10 Years
Min: -0.76  Med: 0.55 Max: 0.91
Current: 0.73
-0.76
0.91
Interest Coverage N/A
ALNY's Interest Coverage is ranked lower than
54% of the 484 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ALNY: N/A )
Ranked among companies with meaningful Interest Coverage only.
ALNY' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: No Debt
Current: N/A
N/A
No Debt
F-Score: 1
Z-Score: 4.56
M-Score: -2.05
WACC vs ROIC
25.63%
-128.90%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -900.33
ALNY's Operating margin (%) is ranked lower than
76% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -88.13 vs. ALNY: -900.33 )
Ranked among companies with meaningful Operating margin (%) only.
ALNY' s Operating margin (%) Range Over the Past 10 Years
Min: -900.33  Med: -188.54 Max: -28.95
Current: -900.33
-900.33
-28.95
Net-margin (%) -869.63
ALNY's Net-margin (%) is ranked lower than
76% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. ALNY: -869.63 )
Ranked among companies with meaningful Net-margin (%) only.
ALNY' s Net-margin (%) Range Over the Past 10 Years
Min: -869.63  Med: -163.4 Max: -27.3
Current: -869.63
-869.63
-27.3
ROE (%) -37.37
ALNY's ROE (%) is ranked lower than
52% of the 874 Companies
in the Global Biotechnology industry.

( Industry Median: -34.32 vs. ALNY: -37.37 )
Ranked among companies with meaningful ROE (%) only.
ALNY' s ROE (%) Range Over the Past 10 Years
Min: -84.12  Med: -39.64 Max: -13.08
Current: -37.37
-84.12
-13.08
ROA (%) -30.78
ALNY's ROA (%) is ranked higher than
50% of the 972 Companies
in the Global Biotechnology industry.

( Industry Median: -30.23 vs. ALNY: -30.78 )
Ranked among companies with meaningful ROA (%) only.
ALNY' s ROA (%) Range Over the Past 10 Years
Min: -48.05  Med: -23.41 Max: -5.01
Current: -30.78
-48.05
-5.01
ROC (Joel Greenblatt) (%) -687.45
ALNY's ROC (Joel Greenblatt) (%) is ranked lower than
56% of the 925 Companies
in the Global Biotechnology industry.

( Industry Median: -407.53 vs. ALNY: -687.45 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ALNY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -2120.98  Med: -554.62 Max: -149.42
Current: -687.45
-2120.98
-149.42
Revenue Growth (3Y)(%) -10.40
ALNY's Revenue Growth (3Y)(%) is ranked lower than
67% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. ALNY: -10.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ALNY' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -8.15 Max: 108
Current: -10.4
0
108
EBITDA Growth (3Y)(%) 52.70
ALNY's EBITDA Growth (3Y)(%) is ranked higher than
90% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. ALNY: 52.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ALNY' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -64.8  Med: 3.5 Max: 65.3
Current: 52.7
-64.8
65.3
EPS Growth (3Y)(%) 48.90
ALNY's EPS Growth (3Y)(%) is ranked higher than
91% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: -3.10 vs. ALNY: 48.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ALNY' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -66.7  Med: 6.6 Max: 52.8
Current: 48.9
-66.7
52.8
GuruFocus has detected 3 Warning Signs with Alnylam Pharmaceuticals Inc $ALNY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ALNY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

ALNY Guru Trades in Q1 2016

Jim Simons 214,000 sh (New)
Vanguard Health Care Fund 8,512,270 sh (+12.25%)
John Griffin 1,075,000 sh (unchged)
John Paulson 12,300 sh (unchged)
Mairs and Power Sold Out
George Soros Sold Out
» More
Q2 2016

ALNY Guru Trades in Q2 2016

Dodge & Cox 2,516,669 sh (New)
John Paulson 19,300 sh (+56.91%)
John Griffin 1,320,000 sh (+22.79%)
Vanguard Health Care Fund 8,512,270 sh (unchged)
Jim Simons 18,673 sh (-91.27%)
» More
Q3 2016

ALNY Guru Trades in Q3 2016

Dodge & Cox 5,276,068 sh (+109.64%)
Vanguard Health Care Fund 8,512,270 sh (unchged)
John Griffin 1,320,000 sh (unchged)
John Paulson 19,300 sh (unchged)
Jim Simons Sold Out
» More
Q4 2016

ALNY Guru Trades in Q4 2016

Dodge & Cox 9,204,950 sh (+74.47%)
Vanguard Health Care Fund 8,549,357 sh (+0.44%)
John Paulson 19,300 sh (unchged)
John Griffin 1,320,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with ALNY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:TECH, NAS:ARIA, NAS:ACAD, NAS:GLPG, NAS:ICPT, NAS:RARE, NAS:CBPO, NAS:CLVS, NAS:BLUE, NYSE:XON, NAS:KITE, OTCPK:BTGGF, NAS:IONS, NAS:JUNO, NAS:SAGE, NAS:AGIO, NAS:LGND, OTCPK:ABCZF, NAS:NKTR, NAS:ONCE » details
Traded in other countries:DUL.Germany,
Alnylam Pharmaceuticals Inc is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi.

Alnylam Pharmaceuticals Inc was originally incorporated in Delaware under the name Alnylam Holding Co. on May 8, 2003. It is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The Company's research and development is focused on use of its proprietary N-acetylgalactosamine, or GalNAc-conjugate for delivery of small interfering RNAs, or "siRNAs" - the molecules that mediate RNAi - toward liver-expressed genes involved in the cause or pathway of human diseases. It is also focused on clinical indications where there are high unmet medical needs, early biomarkers for the assessment of clinical activity in Phase 1 clinical studies, and a definable path for drug development, regulatory approval and commercialization. The Company operates in a single reporting segment, the discovery, development and commercialization of RNAi therapeutics. Its competitors include paten, Kyowa Hakko Kirin, Marina Biotech, Inc., Arrowhead and its subsidiary, Calando Pharmaceuticals, Inc., or Calando, Quark Pharmaceuticals, Inc., or Quark, Silence Therapeutics plc, Tekmira, Sylentis, S.A.U., or Sylentis, Dicerna Pharmaceuticals, Inc. and Arcturus Therapeutics, among others. The research, testing, manufacture and marketing of drug products and their delivery systems are extensively regulated in the United States and the rest of the world.

Top Ranked Articles about Alnylam Pharmaceuticals Inc

Weekly Top Insider Buys Highlight for Week of Oct. 14 Top insider buys of the week, including Monsanto, Alnylam Pharmaceuticals, Synergy Resources and Ferrellgas Partners
Largest Insider buys for Monsanto (NYSE:MON), Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), Synergy Resources Corp. (SYRG) and Ferrellgas Partners LP (NYSE:FGP). Read more...
Low Valuation Ratios Lead to Strong Portfolio Returns Backtesting Ben Graham’s Lost Formula strategy
Known as the “Father of Value Investing,” Benjamin Graham intelligently invested money in the stock market. Read more...

Ratios

vs
industry
vs
history
P/B 4.29
ALNY's P/B is ranked lower than
59% of the 1106 Companies
in the Global Biotechnology industry.

( Industry Median: 3.65 vs. ALNY: 4.29 )
Ranked among companies with meaningful P/B only.
ALNY' s P/B Range Over the Past 10 Years
Min: 2.07  Med: 4.71 Max: 21.37
Current: 4.29
2.07
21.37
P/S 83.39
ALNY's P/S is ranked lower than
81% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: 12.50 vs. ALNY: 83.39 )
Ranked among companies with meaningful P/S only.
ALNY' s P/S Range Over the Past 10 Years
Min: 3.09  Med: 20.67 Max: 222.15
Current: 83.39
3.09
222.15
EV-to-EBIT -8.19
ALNY's EV-to-EBIT is ranked lower than
99.99% of the 284 Companies
in the Global Biotechnology industry.

( Industry Median: 19.01 vs. ALNY: -8.19 )
Ranked among companies with meaningful EV-to-EBIT only.
ALNY' s EV-to-EBIT Range Over the Past 10 Years
Min: -61.7  Med: -10.4 Max: -1.3
Current: -8.19
-61.7
-1.3
EV-to-EBITDA -8.49
ALNY's EV-to-EBITDA is ranked lower than
99.99% of the 307 Companies
in the Global Biotechnology industry.

( Industry Median: 19.22 vs. ALNY: -8.49 )
Ranked among companies with meaningful EV-to-EBITDA only.
ALNY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -95.7  Med: -11.35 Max: -1.4
Current: -8.49
-95.7
-1.4
Current Ratio 5.10
ALNY's Current Ratio is ranked higher than
57% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. ALNY: 5.10 )
Ranked among companies with meaningful Current Ratio only.
ALNY' s Current Ratio Range Over the Past 10 Years
Min: 1.88  Med: 4.77 Max: 17.8
Current: 5.1
1.88
17.8
Quick Ratio 5.10
ALNY's Quick Ratio is ranked higher than
58% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: 3.91 vs. ALNY: 5.10 )
Ranked among companies with meaningful Quick Ratio only.
ALNY' s Quick Ratio Range Over the Past 10 Years
Min: 1.88  Med: 4.77 Max: 17.8
Current: 5.1
1.88
17.8
Days Sales Outstanding 180.60
ALNY's Days Sales Outstanding is ranked lower than
88% of the 592 Companies
in the Global Biotechnology industry.

( Industry Median: 62.87 vs. ALNY: 180.60 )
Ranked among companies with meaningful Days Sales Outstanding only.
ALNY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.57  Med: 34.48 Max: 288.31
Current: 180.6
0.57
288.31

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -10.50
ALNY's 3-Year Average Share Buyback Ratio is ranked higher than
52% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. ALNY: -10.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ALNY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -331.8  Med: -15.2 Max: -1
Current: -10.5
-331.8
-1

Valuation & Return

vs
industry
vs
history
Price/Net Cash 13.88
ALNY's Price/Net Cash is ranked lower than
77% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: 5.89 vs. ALNY: 13.88 )
Ranked among companies with meaningful Price/Net Cash only.
ALNY' s Price/Net Cash Range Over the Past 10 Years
Min: 4.44  Med: 11.31 Max: 42.87
Current: 13.88
4.44
42.87
Price/Net Current Asset Value 12.00
ALNY's Price/Net Current Asset Value is ranked lower than
77% of the 879 Companies
in the Global Biotechnology industry.

( Industry Median: 5.57 vs. ALNY: 12.00 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ALNY' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 4.31  Med: 10.54 Max: 39.45
Current: 12
4.31
39.45
Price/Tangible Book 4.29
ALNY's Price/Tangible Book is ranked lower than
51% of the 1015 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. ALNY: 4.29 )
Ranked among companies with meaningful Price/Tangible Book only.
ALNY' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.65  Med: 5.09 Max: 15.16
Current: 4.29
2.65
15.16
Price/Median PS Value 4.04
ALNY's Price/Median PS Value is ranked lower than
93% of the 765 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. ALNY: 4.04 )
Ranked among companies with meaningful Price/Median PS Value only.
ALNY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.2  Med: 1.06 Max: 9.22
Current: 4.04
0.2
9.22
Earnings Yield (Greenblatt) (%) -12.20
ALNY's Earnings Yield (Greenblatt) (%) is ranked lower than
61% of the 1203 Companies
in the Global Biotechnology industry.

( Industry Median: -9.03 vs. ALNY: -12.20 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ALNY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -18.85  Med: 465.9 Max: 1781.6
Current: -12.2
-18.85
1781.6

More Statistics

Revenue (TTM) (Mil) $47.16
EPS (TTM) $ -4.78
Beta3.16
Short Percentage of Float11.10%
52-Week Range $31.38 - 80.11
Shares Outstanding (Mil)86.01

Analyst Estimate

Dec17
Revenue (Mil $)
EPS ($) -4.41
EPS w/o NRI ($) -4.41
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for ALNY

Headlines

Articles On GuruFocus.com
Weekly Top Insider Buys Highlight for Week of Oct. 14 Oct 16 2016 
Low Valuation Ratios Lead to Strong Portfolio Returns Sep 13 2016 
Liberty Broadband, Hanmi Bank Among Popular Micro-Cap Stocks Apr 04 2016 
Weekly Insider Sells Highlights: Facebook, PacWest Bancorp, Waste Management, Alnylam Pharmaceutical Nov 17 2015 
Julian Robertson Boosts His Stakes in JD.com, Netflix Oct 06 2015 
Julian Robertson Adds 16 New Stakes to Portfolio Jun 23 2015 
Gurus Purchase Tekmira Pharmaceuticals in Q1 Jun 19 2015 
Arrowhead Research Making Headway In The RNAi Therapy Platform Mar 09 2015 
Weekly CEO Buys Highlight: ULBI, BDE, ALNY, CTTR, GFN Feb 27 2012 
Weekly CEO Buys Highlight: VITC, CTFO, RPM, EFC, ALNY Oct 17 2011 

More From Other Websites
ALNYLAM PHARMACEUTICALS, INC. Financials Feb 22 2017
ALNYLAM PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report Feb 15 2017
ETFs with exposure to Alnylam Pharmaceuticals, Inc. : February 14, 2017 Feb 14 2017
Alnylam Pharmaceuticals, Inc. :ALNY-US: Earnings Analysis: 2016 By the Numbers : February 13, 2017 Feb 13 2017
This Healthy Snack Maker Is One of 5 Stocks Ready for a Major Breakout Feb 10 2017
Alnylam Pharmaceuticals, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Feb 10 2017
Alnylam Pharmaceuticals, Inc. :ALNY-US: Earnings Analysis: Q4, 2016 By the Numbers : February 10,... Feb 10 2017
Alnylam's Healthy Earnings Boost Price, Prompts Vetr Users To Call Hold Feb 09 2017
​Alnylam shares jump on positive earnings, 2017 outlook Feb 09 2017
Alnylam (ALNY) Q3 Loss Narrower than Expected, Revenues Rise Feb 09 2017
Edited Transcript of ALNY earnings conference call or presentation 8-Feb-17 9:30pm GMT Feb 09 2017
ALNYLAM PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Feb 08 2017
Alnylam reports 4Q loss Feb 08 2017
Alnylam reports 4Q loss Feb 08 2017
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights... Feb 08 2017
Q4 2016 Alnylam Pharmaceuticals Inc Earnings Release - After Market Close Feb 08 2017
Alnylam to Webcast Presentation at Leerink Partners 6th Annual Global Healthcare Conference Feb 07 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)